NOMAD Power Solutions (NMAD) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily targeting protein phosphatase 2A (PP2A) inhibitors to enhance the efficacy of chemotherapy and immunotherapy.

• Lead compound LB-100 is in clinical trials for ovarian clear cell carcinoma, metastatic microsatellite stable colon cancer, and advanced soft tissue sarcoma.

• Operates with minimal overhead, raising funds at key milestones, and aims for strategic partnerships or licensing agreements with major pharmaceutical companies.

• Holds a robust patent portfolio covering composition, synthesis, and use of LB-100 and analogs, with patents issued in multiple jurisdictions.

Financial performance and metrics

• Reported net losses of $3.59 million in 2024 and $5.09 million in 2023; net loss of $709,555 for Q1 2025.

• Cash balance as of March 31, 2025 was $1.38 million; post-offering, cash expected to be $6.56 million.

• Accumulated deficit of $52.78 million as of March 31, 2025.

• No revenue-generating operations to date; relies on equity capital and stock-based compensation.

Use of proceeds and capital allocation

• Net proceeds of approximately $5.18 million (or $5.99 million if over-allotment is exercised) expected from the offering.

• Proceeds intended for working capital, general corporate purposes, and funding ongoing clinical trials.

• Plans to expand investor relations and public relations programs over the next 12–18 months, with up to $2 million allocated.